New research suggests that taking metformin, a medication commonly used to manage type 2 diabetes, soon after testing positive for COVID-19 may reduce the risk of developing long COVID by as much as 40% in overweight and obese individuals. The trial, involving 1,126 participants considered to be at higher risk of severe symptoms, found that 6.3% of those who took metformin within three days of testing positive reported a long COVID diagnosis within 10 months, compared with 10.4% who were given a placebo. The study is the first to suggest that medication taken at the earliest stages of COVID-19 may reduce the risk of long COVID. However, the trial did not investigate the effect of metformin on those already suffering from long COVID. The medication is generally considered safe, low-cost and widely accessible but is not suitable for those with a BMI under 25 or under 30 years of age. Some experts suggest that more research is needed, while others warn of potential gastrointestinal side effects and the importance of monitoring kidney function when taking metformin.
Denial of responsibility! TechCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Jessica Irvine is a tech enthusiast specializing in gadgets. From smart home devices to cutting-edge electronics, Jessica explores the world of consumer tech, offering readers comprehensive reviews, hands-on experiences, and expert insights into the coolest and most innovative gadgets on the market.
